[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diabetic-foot-ulcer-treatment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diabetic-foot-ulcer-treatment":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100627724","ai-based-diabetic-foot-recurrence-cohort-100627724",false,"NCT07452354","AI-Based Diabetic Foot Recurrence Cohort","Development and Validation of an AI-Based Wound Alert System With a Home-Based Management Model for a Diabetic Foot Recurrence Cohort","Inclusion Criteria:\n\n* The patient must be aged 18 years or older; have a confirmed diagnosis of type 1 or type 2 diabetes mellitus according to the World Health Organization criteria; the wound etiology attributable to diabetic foot ulcers, with complete wound healing post-treatment defined as a dry wound devoid of exudate, complete epithelialization of both the wound bed and margins, absence of surrounding erythema or edema, and sufficient tensile strength to withstand pressure without dehiscence; voluntary participation in this study with provision of written informed consent.\n\nExclusion Criteria:\n\n* Inability of the patient to cooperate or presence of psychiatric disorders; At the investigator's discretion, the subject is deemed unsuitable for this study or unable to comply with the study requirements.","ALL","18 Years",{"count":19,"type":20},200,"ESTIMATED","3 Months","OBSERVATIONAL","Diabetic foot ulcer (DFU) is a major adverse outcome of diabetes, which itself is one of the most significant chronic diseases. The recurrence of DFU involves multiple risk factors, including altered foot loading patterns, patient compliance, family care capacity, blood glucose monitoring, degree of ischemia, and systemic disease control. Early identification of recurrence signs and timely follow-up interventions are crucial for improving prognosis, reducing disability rates, and lowering healthcare costs. However, traditional follow-up systems lack individualized strategies-such as risk stratification, inflexible follow-up intervals, and insufficient compliance management-often resulting in suboptimal outcomes. High-risk patients prone to recurrence may not be followed up frequently enough for early detection, while low-risk patients may undergo unnecessary visits, increasing burdens on both patients and healthcare providers. This inefficiency contributes significantly to the persistently high rates of disability and mortality among recurrent DFU patients.\n\nEstablishing an individualized follow-up strategy for DFU, supported by advanced technology to address core bottlenecks such as delayed recurrence warnings and inadequate home-based management, represents an effective technical pathway to tackle these issues.\n\nOur center proposes to develop a dedicated DFU cohort with comprehensive active follow-up and a multimodal database encompassing well-defined indicators. We aim to explore a high-risk foot grading system for preventing DFU recurrence and design targeted follow-up protocols. By leveraging AI technology, we intend to build a wound warning system capable of identifying DFU recurrence. Furthermore, we seek to establish a telemedicine and AI-assisted, patient-centered home-based self-management framework for early warning and prevention of DFU recurrence.",[25,26,27,28],"Diabetic Foot Ulcer (DFU)","Diabete Mellitus","Diabetic Foot Ulcer Treatment","Artificial Intelligence (AI) in Diagnosis",[30,27,26,31,28],"Diabetic Foot Ulcer","Reccurrence","NOT_YET_RECRUITING","2026-02-28",{"date":35,"type":36},"2026-03-05","ACTUAL",{"date":38,"type":20},"2026-03-15",{"date":40,"type":20},"2028-12-31",{"name":42,"class":43},"Peking University Third Hospital","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":4},"100608846","chemfoot-debrichem-in-chronic-diabetic-foot-wounds-100608846","NCT07206862","CHEMfoot: DEBRICHEM® in Chronic Diabetic Foot Wounds","Clinical Evaluation of the Addition of DEBRICHEM® to the Routine Management of Chronic Diabetic Foot Wounds: an Open-label Randomized Controlled Trial (CHEMfoot Study)","CHEMfoot","Inclusion Criteria:\n\n* Adults ≥18 years.\n* Diabetic foot ulcer (toe, dorsal, plantar, or lateral foot) persisting ≥4 weeks without improvement.\n* Requires debridement.\n* Wound size 0.5-10 cm².\n* Texas classification 0-IIC (controlled neuro-ischemic ulcers, localized infection only).\n* HbA1c ≤10% in last 3 months. Peripheral arterial disease controlled, no critical limb ischemia (toe pressure \\>50 mmHg OR ankle pressure \\>70 mmHg OR TcPO2 \\>30 mmHg).\n\nExclusion Criteria:\n\n* Allergy to DEBRICHEM® components.\n* Active malignancy, osteomyelitis, fasciitis, exposed cartilage.\n* Revascularization \\\u003C4 weeks prior.\n* Systemic infection.\n* Pregnant or breastfeeding women.\n* Vulnerable populations under legal protection.\n* Participation in another clinical trial.",{"count":54,"type":20},242,"INTERVENTIONAL",[57],"NA","This multicenter, randomized controlled trial will evaluate the effectiveness and safety of DEBRICHEM®, a topical desiccant gel, when added to standard care for chronic diabetic foot wounds. Chronic diabetic foot ulcers affect up to 25% of people with diabetes and are associated with high risks of infection, hospitalization, amputation, and mortality. Biofilm formation plays a key role in wound chronicity and delayed healing. DEBRICHEM® is designed to chemically debride wounds by removing biofilm in a single topical application, potentially accelerating the healing process.\n\nA total of 242 adult patients with chronic diabetic foot ulcers (≥4 weeks, 0.5-10 cm²) will be randomized to receive either conventional wound care plus a single application of DEBRICHEM® or conventional wound care alone. The primary endpoint is the proportion of patients achieving complete wound healing at 20 weeks. Secondary outcomes include wound size reduction, infection rates, pain, quality of life, sleep, healthcare resource use, and safety.",[25,27,60],"Diabetic Foot Wounds",[62,63,64,65,66,67],"chemical debridement","DEBRICHEM","topical desiccating agent","TDA","DFU","diabetic foot ulcer","2025-10-01",{"date":70,"type":36},"2025-10-03",{"date":72,"type":20},"2025-10",{"date":74,"type":20},"2027-02",{"name":76,"class":77},"DEBx Medical B.V.","INDUSTRY",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":55,"phases":87,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":44},"100531255","phase-4-multi-center-clinical-observation-and-mechanism-study-of-yunnan-baiyao-in-different-stages-of-diabetic-foot-ulcer-100531255","NCT06197412","Multi-center Clinical Observation and Mechanism Study of Yunnan Baiyao in Different Stages of Diabetic Foot Ulcer","Inclusion Criteria:\n\n1. The age of the subjects is 18-80 years old;\n2. Diagnose diabetes according to WHO standards;\n3. Diagnosis of Diabetic foot;\n4. Confirmed as one of the stages of infection progression and granulation growth;\n5. Voluntarily participate in this study and sign an informed consent form.\n\nExclusion Criteria:\n\n1. Severe diseases such as acute myocardial infarction, heart failure, hepatitis, shock, and respiratory failure have not been corrected yet;\n2. Blood glucose is out of control, Glucose test#Fasting blood sugar\\>15mmol \u002FL, Glycated hemoglobin\\>12%;\n3. There is active bleeding inside the wound, and routine basic treatment plans cannot be implemented;\n4. Serum albumin\\<20g\u002FL; Hemoglobin\\<60g\u002FL; Platelets\\<50 × 109\u002FL;\n5. Late stage subjects with malignant tumors;\n6. Active period of autoimmune diseases;\n7. Have a history of allergy to Yunnan Baiyao;\n8. The subject is unable to cooperate or has mental disorders;\n9. According to the judgment of the researcher, the subject has a clear reason that cannot be removed and affects wound healing, which is not suitable for this study or cannot comply with the requirements of this study.","80 Years",{"count":86,"type":20},100,[88],"PHASE4","Yunnan Baiyao has been treating all kinds of wounds for 120 years, but the evidence of Evidence-based medicine that is truly convincing is insufficient, making its best application method unclear. This study explored the possible indications and use methods of Yunnan Baiyao in different stages of Diabetic foot, and obtained Evidence-based medicine evidence of clinical efficacy. Obtain the discarded tissues of Diabetic foot patients in the treatment and control groups of Yunnan Baiyao after wound debridement, conduct Transcriptome (BulkRNA seq) analysis and detection on the wound tissues, and analyze the related signal pathways and functional genes with significant differences, to help clarify the possible treatment targets of Yunnan Baiyao.",[27],"RECRUITING","2024-06-30",{"date":94,"type":36},"2024-07-03",{"date":96,"type":36},"2023-12-01",{"date":98,"type":20},"2026-03-31",{"name":42,"class":43}]